EULAR/ACR Classification in MDA5+ Myositis Patients

Save

The diagnosis of idiopathic inflammatory myopathies (IIMs) can be informed by the 2017 EULAR/ACR classification criteria, but their utility in patients with clinically amyopathic dermatomyositis (CADM) and anti–melanoma differentiation–associated protein 5 (anti–MDA-5)–positive IIM

FDA Approves BA.4 and BA.5 Omicron COVID Booster Vaccines

Save

Today the FDA authorized the updated Omicron subvariant (BA.4 and BA.5) COVID-19 booster shots manufactured by Pfizer and Moderna; with an anticipated ship/start date of early September 2022. The BA.5 subvariant accounts for more than 88% of U.S. infections.

NICE Guidelines on Gout Diagnosis and Management

Save

NICE (UK) has systematically reviewed current medical evidence and delivered a set of recommendations with consideration of cost effectiveness.

Disease Activity Scoring in Adult-onset Still's disease

Save

Still's disease in adults (AOSD) or children (sJIA) can have dramatic symptom severity, making it easy to gauge disease activity and response to therapy, especially at the outset. However, a validated measure of disease activity has not been agreed (for clinical trial and treatment assessments). A new study compares two such activity measuresin a large cohort of Still's patients.

STING/IFN Activation Promotes ANCA-Associated Vasculitis Progression

Save

Research presented in the Journal of Experimental Medicine shows that ANCA-associated vasculitis (AAV) may be propagated by pathogenic mechanisms triggering cGAS/STING/IRF3-dependent IFN-I release.

Autoimmune Disease Augments Cardiovascular Risk

Save

A large UK database study suggests that young adults with autoimmune diseases have an associated increased risk for cardiovascular disease.

RheumNow Podcast –Rainbow Rheumatology (8.27.2022)

Save

Dr. Jack Cush delivers this weeks rheumatology "weather report" with the best and least of news and journal articles from the past week on RheumNow.com

“Climate is what we expect, weather is what we get.” – Mark Twain

Olokizumab, another IL-6 Inhibitor for RA

Save

This week's NEJM has published the efficacy results of a large phase 3 trial of olokizumab, a humanized monoclonal antibody that directly targets IL-6 in patients with rheumatoid arthritis.

This is in contrast to two other marketed IL-6 inhibitors (sarilumab, tocilizumab) that bind to the IL-6 receptor.

Hyaluronic Acid Knee Injections Equivalent to Placebo

Save

In the United States, where over $300 million is spent annually on intraarticular hyaluronic acid injections, yet another study shows such therapy to be no better than placebo.

Bullous Systemic Lupus Erythematosus

Save

Bullous systemic lupus erythematosus (BSLE) is a rare blistering cutaneous manifestation of systemic lupus erythematosus (SLE).

As goes SLE, bullous disease typically affects women, especially those of African descent.

Weight Loss Slows Knee OA Progression

Save

Declines in body mass index (BMI) were linked with slower worsening of knee osteoarthritis (OA), according to data from three large longitudinal cohort studies.

Axial Psoriatic Arthritis and Ankylosing Spondylitis with Psoriasis

Save

A cohort analysis from Toronto suggests that axial psoriatic arthritis (PsA) is distinctly different from axial ankylosing spondylitis (AS) with psoriasis.

What to do with "no-shows"

Save

A current Medscape article on patient "no shows" in private medical practice examines the cause and approach to the problem.

The most common reason for no shows is lack of knowledge about the scheduled appointment. Here are other common causes of no-shows, and how to address the problem.

Managing JDM with Calcinosis

Save

Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow and discusses a case of refractory juvenile dermatomyositis with calcinosis.

Melatonin Use Growing, Inappropriate & Potentially Unsafe

Save

With nearly one-third of adults, adolescents and children having sleep difficulties, many resort to using melatonin. JAMA reports substantial increases in the use of over-the-counter (OTC) melatonin, in all age groups. But is it effective, safe and warranted?

Rituximab Efficacy in Systemic Sclerosis

Save

The DESIRES trial studied rituximab (RTX) in patients with systemic sclerosis (SSc) and showed clinically significant improvement in skin and lung outcomes after a subsequent 24-week open-label extension phase.

Low Dose IL-2 Therapy in SLE

Save

A multicentre, proof-of-concept trial of suggests that low-dose IL-2 therapy may be effective in moderate-to-severe systemic lupus erythematosus (SLE).

Favorable Pregnancy Outcomes in Spondyloarthritis

Save

Pregnancy often occurs in women with axial spondyloarthritis (axSpA), and a recent cohort study suggests outcomes are generally better than what had been reported in the literature.

JUNIPERA Study - Secukinumab in Juvenile PsA & ERA

Save

JUNIPERA study evaluated secukinumab (SEC) in children with enthesitis-related arthritis (ERA) and juvenile psoriatic arthritis (JPsA) and was found to be safe and effective in patients with active ERA and JPsA who previous failed to respond to conventional therapy.